{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T04:31:48Z","timestamp":1792729908874,"version":"4.5.0"},"reference-count":68,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.jaci.2020.08.041","type":"journal-article","created":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T11:07:04Z","timestamp":1601550424000},"page":"1369-1380","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":119,"title":["Mild atopic dermatitis lacks systemic inflammation and shows reduced nonlesional skin abnormalities"],"prefix":"10.1016","volume":"147","author":[{"given":"Helen","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ester","family":"Del Duca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aisleen","family":"Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun Je","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"Gay-Mimbrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianni","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Beaziz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeriel","family":"Estrada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James G.","family":"Krueger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana B.","family":"Pavel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Ruano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9363-324X","authenticated-orcid":false,"given":"Emma","family":"Guttman-Yassky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2020.08.041_bib1","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.jid.2018.08.028","article-title":"Atopic Dermatitis in America Study: a cross-sectional study examining the prevalence and disease burden of atopic dermatitis in the US adult population","volume":"139","author":"Chiesa Fuxench","year":"2019","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2020.08.041_bib2","doi-asserted-by":"crossref","first-page":"82","DOI":"10.2310\/6620.2007.06034","article-title":"A population-based survey of eczema prevalence in the United States","volume":"18","author":"Hanifin","year":"2007","journal-title":"Dermatitis"},{"key":"10.1016\/j.jaci.2020.08.041_bib3","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s11882-014-0433-9","article-title":"Skin barrier defects in atopic dermatitis","volume":"14","author":"Agrawal","year":"2014","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1016\/j.jaci.2020.08.041_bib4","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1016\/j.jaci.2017.04.004","article-title":"Novel concepts of prevention and treatment of atopic dermatitis through barrier and immune manipulations with implications for the atopic march","volume":"139","author":"Czarnowicki","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2020.08.041_bib5","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.jaci.2012.07.012","article-title":"Progressive activation of T(H)2\/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis","volume":"130","author":"Gittler","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2020.08.041_bib6","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/j.1600-065X.2011.01027.x","article-title":"Atopic dermatitis: a disease of altered skin barrier and immune dysregulation","volume":"242","author":"Boguniewicz","year":"2011","journal-title":"Immunol Rev"},{"key":"10.1016\/j.jaci.2020.08.041_bib7","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/j.jaci.2015.03.003","article-title":"RNA sequencing atopic dermatitis transcriptome profiling provides insights into novel disease mechanisms with potential therapeutic implications","volume":"135","author":"Suarez-Farinas","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2020.08.041_bib8","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jaci.2015.01.020","article-title":"Severe atopic dermatitis is characterized by selective expansion of circulating TH2\/TC2 and TH22\/TC22, but not TH17\/TC17, cells within the skin-homing T-cell population","volume":"136","author":"Czarnowicki","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2020.08.041_bib9","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jaci.2015.08.027","article-title":"Diverse activation and differentiation of multiple B-cell subsets in patients with atopic dermatitis but not in patients with psoriasis","volume":"137","author":"Czarnowicki","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2020.08.041_bib10","doi-asserted-by":"crossref","first-page":"8707","DOI":"10.1038\/s41598-017-09207-z","article-title":"The atopic dermatitis blood signature is characterized by increases in inflammatory and cardiovascular risk proteins","volume":"7","author":"Brunner","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.jaci.2020.08.041_bib11","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1016\/j.jaci.2017.12.991","article-title":"Serum biomarker profiles suggest that atopic dermatitis is a systemic disease","volume":"141","author":"Thijs","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2020.08.041_bib12","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.jaad.2019.10.039","article-title":"The proteomic skin profile of moderate-to-severe atopic dermatitis patients shows an inflammatory signature","volume":"82","author":"Pavel","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2020.08.041_bib13","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.anai.2019.10.013","article-title":"Increased cardiovascular and atherosclerosis markers in blood of older patients with atopic dermatitis","volume":"124","author":"He","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2020.08.041_bib14","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.jid.2016.09.037","article-title":"An integrated model of atopic dermatitis biomarkers highlights the systemic nature of the disease","volume":"137","author":"Ungar","year":"2017","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2020.08.041_bib15","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.jaci.2010.12.1124","article-title":"Nonlesional atopic dermatitis skin is characterized by broad terminal differentiation defects and variable immune abnormalities","volume":"127","author":"Suarez-Farinas","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2020.08.041_bib16","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jaci.2018.08.022","article-title":"Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis","volume":"143","author":"Guttman-Yassky","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2020.08.041_bib17","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis","volume":"375","author":"Simpson","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2020.08.041_bib18","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jaci.2018.05.029","article-title":"Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb","volume":"143","author":"Wollenberg","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2020.08.041_bib19","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s40257-018-0413-2","article-title":"JAK Inhibitors for atopic dermatitis: an update","volume":"20","author":"He","year":"2019","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaci.2020.08.041_bib20","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.jaci.2019.07.013","article-title":"Oral Janus kinase\/SYK inhibition (ASN002) suppresses inflammation and improves epidermal barrier markers in patients with atopic dermatitis","volume":"144","author":"Pavel","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2020.08.041_bib21","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/bjd.17932","article-title":"The oral Janus kinase\/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate-to-severe atopic dermatitis: results from a randomized double-blind placebo-controlled study","volume":"181","author":"Bissonnette","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2020.08.041_bib22","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.jaad.2018.01.017","article-title":"Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: a randomized, placebo-controlled phase II trial (TREBLE)","volume":"78","author":"Simpson","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2020.08.041_bib23","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jaci.2019.08.013","article-title":"Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus","volume":"145","author":"Silverberg","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2020.08.041_bib24","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.jaci.2014.10.013","article-title":"Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis","volume":"134","author":"Hamilton","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2020.08.041_bib25","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2340\/00015555-3053","article-title":"Characteristics of pruritus in relation to self-assessed severity of atopic dermatitis","volume":"99","author":"Huet","year":"2019","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaci.2020.08.041_bib26","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/DER.0000000000000406","article-title":"Pain and itch are dual burdens in atopic dermatitis","volume":"29","author":"Maarouf","year":"2018","journal-title":"Dermatitis"},{"key":"10.1016\/j.jaci.2020.08.041_bib27","doi-asserted-by":"crossref","DOI":"10.1001\/jamapediatrics.2019.0025","article-title":"Association of atopic dermatitis with sleep quality in children","author":"Ramirez","year":"2019","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.jaci.2020.08.041_bib28","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jaci.2009.11.027","article-title":"Recent insights into atopic dermatitis and implications for management of infectious complications","volume":"125","author":"Boguniewicz","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2020.08.041_bib29","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/exd.12967","article-title":"Distinct molecular signatures of mild extrinsic and intrinsic atopic dermatitis","volume":"25","author":"Martel","year":"2016","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jaci.2020.08.041_bib30","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1067\/mai.2003.114","article-title":"Increased serum cutaneous T cell-attracting chemokine (CCL27) levels in patients with atopic dermatitis and psoriasis vulgaris","volume":"111","author":"Kakinuma","year":"2003","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2020.08.041_bib31","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1034\/j.1399-3038.2003.00052.x","article-title":"Serum concentration of macrophage-derived chemokine may be a useful inflammatory marker for assessing severity of atopic dermatitis in infants and young children","volume":"14","author":"Leung","year":"2003","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.jaci.2020.08.041_bib32","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1046\/j.1365-2249.2002.01727.x","article-title":"Serum macrophage-derived chemokine (MDC) levels are closely related with the disease activity of atopic dermatitis","volume":"127","author":"Kakinuma","year":"2002","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jaci.2020.08.041_bib33","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.jaci.2003.12.007","article-title":"Serum thymus and activation-regulated chemokine (TARC) and cutaneous T cell- attracting chemokine (CTACK) levels in allergic diseases: TARC and CTACK are disease-specific markers for atopic dermatitis","volume":"113","author":"Hijnen","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2020.08.041_bib34","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/j.1398-9995.2005.00774.x","article-title":"Serum thymus and activation-regulated chemokine, macrophage-derived chemokine and eotaxin as markers of severity of atopic dermatitis","volume":"60","author":"Jahnz-Rozyk","year":"2005","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2020.08.041_bib35","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/j.1399-3038.2007.00692.x","article-title":"Serum levels of Th2 chemokines, CCL17, CCL22, and CCL27, were the important markers of severity in infantile atopic dermatitis","volume":"19","author":"Nakazato","year":"2008","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.jaci.2020.08.041_bib36","doi-asserted-by":"crossref","first-page":"e261","DOI":"10.1111\/ijd.12830","article-title":"Serum levels of thymus and activation-regulated chemokine can be used in the clinical evaluation of atopic dermatitis","volume":"54","author":"Gu","year":"2015","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaci.2020.08.041_bib37","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1111\/pai.12744","article-title":"An association of periostin levels with the severity and chronicity of atopic dermatitis in children","volume":"28","author":"Sung","year":"2017","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.jaci.2020.08.041_bib38","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/j.0736-8046.2004.21600.x","article-title":"Serum concentration of IL-18 correlates with disease extent in young children with atopic dermatitis","volume":"21","author":"Hon","year":"2004","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.jaci.2020.08.041_bib39","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/ijd.13579","article-title":"Expression levels of transcription factor PU.1 and interleukin-9 in atopic dermatitis and their relation to disease severity and eruption types","volume":"56","author":"Hamza","year":"2017","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaci.2020.08.041_bib40","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.imlet.2017.04.010","article-title":"Expansion of circulating follicular T helper cells associates with disease severity in childhood atopic dermatitis","volume":"189","author":"Szabo","year":"2017","journal-title":"Immunol Lett"},{"key":"10.1016\/j.jaci.2020.08.041_bib41","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1046\/j.1365-2133.2002.04803.x","article-title":"Nerve growth factor and substance P are useful plasma markers of disease activity in atopic dermatitis","volume":"147","author":"Toyoda","year":"2002","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2020.08.041_bib42","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.anai.2017.06.022","article-title":"Eosinophil-derived neurotoxin as a biomarker for disease severity and relapse in recalcitrant atopic dermatitis","volume":"119","author":"Kim","year":"2017","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2020.08.041_bib43","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1046\/j.1365-2133.1998.02120.x","article-title":"Soluble E-selectin, other markers of inflammation and disease severity in children with atopic dermatitis","volume":"138","author":"Wolkerstorfer","year":"1998","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2020.08.041_bib44","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1097\/ACI.0000000000000198","article-title":"Biomarkers for atopic dermatitis: a systematic review and meta-analysis","volume":"15","author":"Thijs","year":"2015","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2020.08.041_bib45","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1016\/j.jid.2016.04.032","article-title":"The spectrum of mild to severe psoriasis vulgaris is defined by a common activation of il-17 pathway genes, but with key differences in immune regulatory genes","volume":"136","author":"Kim","year":"2016","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2020.08.041_bib46","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.jaci.2011.05.042","article-title":"Reversal of atopic dermatitis with narrow-band UVB phototherapy and biomarkers for therapeutic response","volume":"128","author":"Tintle","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2020.08.041_bib47","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0095192","article-title":"Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability","volume":"9","author":"Assarsson","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jaci.2020.08.041_bib48","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.atherosclerosis.2015.07.023","article-title":"Use of a proximity extension assay proteomics chip to discover new biomarkers for human atherosclerosis","volume":"242","author":"Lind","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jaci.2020.08.041_bib49","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.jaci.2015.08.015","article-title":"The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased TH17 polarization","volume":"136","author":"Noda","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2020.08.041_bib50","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.jaci.2009.03.041","article-title":"IL-22-producing \"T22\" T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17-producing TH17 T cells","volume":"123","author":"Nograles","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2020.08.041_bib51","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.jaci.2012.07.008","article-title":"The persistence of atopic dermatitis and filaggrin (FLG) mutations in a US longitudinal cohort","volume":"130","author":"Margolis","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2020.08.041_bib52","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jaci.2019.01.015","article-title":"Age-specific changes in the molecular phenotype of patients with moderate-to-severe atopic dermatitis","volume":"144","author":"Zhou","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2020.08.041_bib53","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.jaci.2018.02.047","article-title":"Serum from Asian patients with atopic dermatitis is characterized by TH2\/TH22 activation, which is highly correlated with nonlesional skin measures","volume":"142","author":"Wen","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2020.08.041_bib54","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jaci.2013.04.046","article-title":"Intrinsic atopic dermatitis shows similar TH2 and higher TH17 immune activation compared with extrinsic atopic dermatitis","volume":"132","author":"Suarez-Farinas","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2020.08.041_bib55","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/j.jaci.2020.01.042","article-title":"Single-cell transcriptome analysis of human skin identifies novel fibroblast subpopulation and enrichment of immune subsets in atopic dermatitis","volume":"145","author":"He","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2020.08.041_bib56","doi-asserted-by":"crossref","first-page":"6639","DOI":"10.1038\/s41598-018-25094-4","article-title":"IL-31 is crucial for induction of pruritus, but not inflammation, in contact hypersensitivity","volume":"8","author":"Takamori","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.jaci.2020.08.041_bib57","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.cytogfr.2008.08.003","article-title":"Structures and biological functions of IL-31 and IL-31 receptors","volume":"19","author":"Zhang","year":"2008","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.jaci.2020.08.041_bib58","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.aller.2017.10.005","article-title":"Assessment of IL-31 levels and disease severity in children with atopic dermatitis","volume":"46","author":"Ozceker","year":"2018","journal-title":"Allergol Immunopathol (Madr)"},{"key":"10.1016\/j.jaci.2020.08.041_bib59","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1111\/all.12712","article-title":"Foxp3(+) regulatory T cells are expanded in severe atopic dermatitis patients","volume":"70","author":"Roesner","year":"2015","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2020.08.041_bib60","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1159\/000323305","article-title":"The role of regulatory T cells in atopic dermatitis","volume":"41","author":"Agrawal","year":"2011","journal-title":"Curr Probl Dermatol"},{"key":"10.1016\/j.jaci.2020.08.041_bib61","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1038\/nature05479","article-title":"Regulatory T-cell functions are subverted and converted owing to attenuated Foxp3 expression","volume":"445","author":"Wan","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.jaci.2020.08.041_bib62","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0065-2776(09)01203-6","article-title":"Cellular and molecular mechanisms in atopic dermatitis","volume":"102","author":"Oyoshi","year":"2009","journal-title":"Adv Immunol"},{"key":"10.1016\/j.jaci.2020.08.041_bib63","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.metabol.2018.01.017","article-title":"Fibroblast growth factor 21 in cardio-metabolic disorders: a systematic review and meta-analysis","volume":"83","author":"Lakhani","year":"2018","journal-title":"Metabolism"},{"key":"10.1016\/j.jaci.2020.08.041_bib64","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1159\/000486127","article-title":"Serum FGF21 is associated with future cardiovascular events in patients with coronary artery disease","volume":"139","author":"Shen","year":"2018","journal-title":"Cardiology"},{"key":"10.1016\/j.jaci.2020.08.041_bib65","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1134\/S0026893311030125","article-title":"[Methylation profiling of human atherosclerotic plaques]","volume":"45","author":"Nazarenko","year":"2011","journal-title":"Mol Biol (Mosk)"},{"key":"10.1016\/j.jaci.2020.08.041_bib66","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/1917291","article-title":"Association of circulating IGFBP1 level with the severity of coronary artery lesions in patients with unstable angina","volume":"2017","author":"Zheng","year":"2017","journal-title":"Dis Markers"},{"key":"10.1016\/j.jaci.2020.08.041_bib67","first-page":"35","article-title":"Atopic dermatitis: an overview","volume":"86","author":"Berke","year":"2012","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.jaci.2020.08.041_bib68","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.2337\/dc18-2158","article-title":"Association between topical corticosteroid use and type 2 diabetes in two European population-based adult cohorts","volume":"42","author":"Andersen","year":"2019","journal-title":"Diabetes Care"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674920313348?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674920313348?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T09:30:51Z","timestamp":1758792651000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674920313348"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":68,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S0091674920313348"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2020.08.041","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mild atopic dermatitis lacks systemic inflammation and shows reduced nonlesional skin abnormalities","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2020.08.041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}